THE INFLUENCE OF INFORMATION TRANSPARENCY ON THE VALUE INDICATORS OF SECURITIES DURING THE CRISIS, TAKING INTO ACCOUNT THE TIME HORIZON OF INVESTMENT

Abstract

In the conditions of the turbulence of the stock markets, the low level of publicity and transparency of the published information and the increase of uncertainty regarding the future development of socio-economic processes, it is relevant to analyze the relationship between the risk and the yield of the securities of companies that were most vulnerable to the financial and economic crisis caused by the pandemic Covid-19. The purpose of the article is to analyze indicators of profitability, risk and variability based on the analysis of the value of shares of the analyzed companies in the pharmaceutical, aviation, transport and information industries of the economy in the conditions of financial and economic crisis and global uncertainty. In the process of analysis, it was determined that the most vulnerable to the consequences of the financial and economic crisis are the sectors of the economy that have experienced significant financial, economic, and personnel losses. It has been established that the lack of an adequate level of information transparency is one of the determining factors affecting the investment process and the possibility of obtaining stable returns in the long term. The indicators of the development of stock indices of the London and European stock exchanges FTSE 100 and Euronext were studied. A comparative analysis of the value of shares of industrial enterprises was conducted for the period from 2015 to the beginning of 2023. It has been found that with the growth of the time period of investment, the risk and volatility between the maximum and the minimum rate of return on shares are reduced to a minimum. The aviation sector is the most attractive from the point of view of investment, as the maximum return during the first month of investment is 67.22%. The least attractive, but at the same time the least risky sector of the economy is the pharmaceutical industry, where during the first month of investment it is possible to get 19.36% profit from the invested capital.